127 related articles for article (PubMed ID: 9236054)
1. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly.
Martin JT
Biologicals; 1997 Jun; 25(2):209-13. PubMed ID: 9236054
[TBL] [Abstract][Full Text] [Related]
2. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
3. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
4. Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients.
de Roux A; Marx A; Burkhardt O; Schweiger B; Borkowski A; Banzhoff A; Pletz MW; Lode H
Vaccine; 2006 Mar; 24(10):1537-42. PubMed ID: 16288937
[TBL] [Abstract][Full Text] [Related]
5. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
El Sahly H
Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
[TBL] [Abstract][Full Text] [Related]
6. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
7. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
[TBL] [Abstract][Full Text] [Related]
9. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
10. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
Valensi JP; Carlson JR; Van Nest GA
J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
[TBL] [Abstract][Full Text] [Related]
11. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
12. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
[TBL] [Abstract][Full Text] [Related]
13. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
Joseph A; Itskovitz-Cooper N; Samira S; Flasterstein O; Eliyahu H; Simberg D; Goldwaser I; Barenholz Y; Kedar E
Vaccine; 2006 May; 24(18):3990-4006. PubMed ID: 16516356
[TBL] [Abstract][Full Text] [Related]
14. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
Ansaldi F; Zancolli M; Durando P; Montomoli E; Sticchi L; Del Giudice G; Icardi G
Vaccine; 2010 Jun; 28(25):4123-9. PubMed ID: 20433807
[TBL] [Abstract][Full Text] [Related]
15. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
Ruf BR; Colberg K; Frick M; Preusche A
Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
[TBL] [Abstract][Full Text] [Related]
16. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
O'Hagan DT
Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
[TBL] [Abstract][Full Text] [Related]
17. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile.
Podda A; Del Giudice G
Expert Rev Vaccines; 2003 Apr; 2(2):197-203. PubMed ID: 12899571
[TBL] [Abstract][Full Text] [Related]
18. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with inactivated, virosomal influenza vaccine.
de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
[TBL] [Abstract][Full Text] [Related]
20. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]